Results 121 to 130 of about 86,262 (260)

The association of thrombocytopenia with haematological malignancy

British Journal of Haematology, EarlyView.
This review article discusses the interplay of immune dysregulation, clonality, and immunosuppressive therapies in immune thrombocytopenia and how this links to the risk of misattribution versus the development of haematological malignancy. Unresolved questions and directions for future research are also discussed. Isolated thrombocytopenia is commonly
Abi Vijenthira, Henrik Frederiksen, Michelle Sholzberg   +2 more
wiley   +1 more source

Thrombocytosis and the generation of platelet‐derived microparticles in the pathophysiology of sickle cell disease

British Journal of Haematology, EarlyView.
Thrombocytosis is associated with an increased production of platelet‐derived microparticles from activated platelets, which contribute to vaso‐occlusion in sickle cell disease by perpetuating the cycle of inflammation, procoagulant state and endothelial dysfunction.
Giao N. Lê, Anna Dillon, Owen P. Smith, Corrina McMahon   +3 more
wiley   +1 more source

Clinical and immunological effects of adding cyclophosphamide to pomalidomide–dexamethasone in relapsed‐refractory multiple myeloma: The randomized MUKseven trial

British Journal of Haematology, EarlyView.
Summary There is an ongoing need for accessible combination therapies for patients with relapsed‐refractory multiple myeloma (RRMM), alongside a growing interest in understanding their immunological effects, particularly on T‐cell populations. Myeloma UK (MUK) MUKseven (NCT02406222) was an academic, UK multicentre randomized controlled, open‐label ...
Andrew Hall, James Croft, Katrina Walker, Kevin Boyd, Sadie Roberts, Amy Holroyd, Mamta Garg, Elsa Ferris, Gordon Cook, William E. Pierceall, Anjan Thakurta, Anita Gandhi, Charlotte Pawlyn, Sarah R. Brown, Martin Kaiser   +14 more
wiley   +1 more source

The glycan fingerprint in immune thrombocytopenia. [PDF]

Res Pract Thromb Haemost
Nelson VS, Zlamal J, Kapur R.
europepmc   +1 more source

Diagnosis and management of neutropenia in adults: Expert guidance

British Journal of Haematology, EarlyView.
Severe neutropenia can result from decreased production of neutrophil precursors in the bone marrow, as in the case of severe congenital neutropenia, or from increased utilization of neutrophils or their accelerated destruction as for drug‐induced neutropenia or autoimmune neutropenia. Severe chronic neutropenia increases susceptibility to bacterial or
Karl Welte, Cornelia Zeidler, Julia Skokowa, Sabine Mellor‐Heineke, Audrey Anna Bolyard, David Dale   +5 more
wiley   +1 more source

Severe Persistent Neonatal Immune Thrombocytopenia Despite Optimized Maternal Chronic Immune Thrombocytopenia (ITP) Management. [PDF]

Cureus
Trevino N, Kuffour G, Okogbule-Wonodi A, Wentworth S, Ali A, Bisrat M, Michael M, Reeves I.   +7 more
europepmc   +1 more source

Patient and Physician Experiences in Immune Thrombocytopenia. [PDF]

Adv Ther
Hsu A, Fassett T, Pallagi S, Panch SR.
europepmc   +1 more source

Clinical characteristics, treatment, and outcomes of Oxaliplatin-induced immune thrombocytopenia. [PDF]

Front Immunol
Huang N, Liu Z, Li R, Lei H, Liu X.
europepmc   +1 more source

Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial

British Journal of Haematology, EarlyView.
Summary Avatrombopag treatment resulted in significantly higher platelet response rates in patients when compared with placebo in a phase 3b study of patients with paediatric immune thrombocytopenia (ITP) (NCT04516967). These post hoc analyses of the 12‐week core phase further assessed the efficacy of avatrombopag, considering the influence of baseline
Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Sule Unal, John Grainger, Amanda B. Grimes, Michele P. Lambert, Jessica Zhang, Brian D. Jamieson, Faizan Sattar, Scott Kolodny, Michael Vredenburg, on behalf of the AVA‐PED‐301 Study Group   +12 more
wiley   +1 more source

Factors associated with response to rituximab in patients with immune thrombocytopenia. [PDF]

Hemasphere
Tsykunova G, Kristiansen EB, Tvedt THA, Frederiksen H, Christiansen CF, Linder M, Bahmanyar S, Ghanima W.   +7 more
europepmc   +1 more source